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Circular RNAs (circRNAs) are a type of non-coding RNAs (ncRNAs), produced in
eukaryotic cells during post-transcriptional processes. They are more stable than linear
RNAs, and possess spatio-temporal properties. CircRNAs do not distribute equally in
the neuronal compartments in the brain, but largely enriched in the synapses. These
ncRNA species can be used as potential clinical biomarkers in complex disorders of the
central nervous system (CNS), which is supported by recent findings. For example,
ciRS-7 was found to be a natural microRNAs sponge for miRNA-7 and regulate
Parkinson’s disease/Alzheimer’s disease-related genes; circPAIP2 is an intron-retaining
circRNA which upregulates memory-related parental genes PAIP2 to affect memory
development through PABP reactivation. The quantity of circRNAs carry important
messages, either when they are inside the cells, or in circulation, or in exosomes
released from synaptoneurosomes and endothelial. In addition, small molecules such
as microRNAs and microvesicles can pass through the blood–brain barrier (BBB) and
get into blood. For clinical applications, the study population needs to be phenotypically
well-defined. CircRNAs may be combined with other biomarkers and imaging tools to
improve the diagnostic power.
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INTRODUCTION
Circular RNAs (CircRNAs) are a family of naturally occurring endogenous ncRNAs with
widespread distribution and diverse functions. They are ∼100 nucleotides long (Memczak et al.,
2013) single-stranded RNA molecule forms a circle through covalent binding (Chen et al., 2015),
which are highly represented in the eukaryotic transcriptome and abundant in exosomes. A large
number of circRNAs have been identified, and some have been validated to function as microRNA
sponges in mammal cells through high-throughput RNA sequencing and bioinformatic analysis
(Chen et al., 2015; Li Y. et al., 2015). Another important feature of circRNAs is their spatio-
temporal specific expression which suggests potential regulatory roles (Shen et al., 2015). In
addition, circRNAs have been shown to serve as biomarkers for a potential non-invasive diagnosis
for atherosclerosis (Burd et al., 2010), disorders of the central neural diseases (Lukiw, 2013),
degenerative diseases (Ashwal-Fluss et al., 2014), and cancers (Li P. et al., 2015; Li Y. et al., 2015).
Finding biomarkers for an accurate diagnosis at an early stage is crucial for the treatment of
many complex CNS disorders. For example, oligoclonal bands and IgG ratio is used for prognosis
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and prediction of conversion from clinically isolated syndrome
to multiple sclerosis (MS); JCV Ab seropositive is predictive
for progressive multifocal leukoencephalopathy; and MRI is the
primary tool for determining phase II and III clinical trials for
MS, which has been used in clinic diagnosis and evaluation of
prognosis (Housley et al., 2015); the ratios of tau/Aβ42 and
p-tau/Aβ42 in the CSF can be used in differential diagnosis,
prediction of conversion and the rate of progression from
cognitive normalcy to mild dementia and severe impairment
in Alzheimer’s disease (AD; Jin et al., 2013); imaging markers
including PET and MRI can predict outcome after reperfusion
therapies for acute ischemic stroke (Dani and Warach, 2014).
However, when patients are diagnosed with Parkinson’s disease
(PD), if their dopaminergic neurons have already degenerated
by over 60%; the risk of thrombolysis is difficult to assess
after patients diagnosed with stroke for 4.5 h (Nathaniel et al.,
2015).
CircRNAs are abundant in the brain and exosomes. Their
capability to transverse the blood–brain barrier (Li Y. et al., 2015)
makes them perfect candidates as potential diagnostic tools for
CNS disorders. The circRNAs are enriched by at least twofold
in exosomes compared to those retained in the cells (Li Y. et al.,
2015), so what could be detected in the human blood may provide
information about the disease status in the CNS. Therefore, this
mini-review will provide a new approach for biomarker studies in
CNS disease area by integrating the circRNAs-related literatures.
CircRNAs Regulated in CNS Functions
and Disorders
Rybak-Wolf et al. (2015) have detected 15,849 circRNA
candidates with distinct spatio-temporal expression pattern in
mouse and 65,731 in human brain samples. These RNAs are
generated from “back-splicing” annotated exons during post-
transcriptional processes with a clear preference for coding
sequence (CDS) and 5′ untranslated region (UTR) exons
(Westholm et al., 2014; Rybak-Wolf et al., 2015). After systematic
investigation, unique circRNAs are often differentially expressed
in mammalian cells. For example, mouse circRNA generated
from Rims2 in the adult brain is expressed 20-fold higher than
the linear mRNA, but is lowly expressed in other mouse tissues
(Rybak-Wolf et al., 2015); circRims2, circElf2, and circDym
are enriched in the cerebellum, while circPlxnd1is enriched
in the cortex (Rybak-Wolf et al., 2015); circRNA CiRS-7 is
the most highly expressed circRNA in cerebellum of E115 but
lowly express in cortex at E60 during porcine embryonic brain
development (Veno et al., 2015), which suggests that some
circRNAs expression increases during development of the central
nervous system (CNS) to augment density of miRNA target
sites with respect to the bulk linear coding regions (Westholm
et al., 2014). In addition, circRNAs may decrease during cell
proliferation in some cancer cells (Bachmayr-Heyda et al., 2015;
Chen et al., 2015). A large proportion of circRNAs are abundant
in brain, but circRNAs are inequally distributed in the neuronal
compartments. with the highest expression in the synapses for
brain development or synaptic plasticity. This may explain that
fact that synaptic density in the human cerebral cortex may be
four times higher than in the mouse brain (Herculano-Houzel,
2009; Veno et al., 2015).
ciRS-7 contains more than 70 selectively conserved miRNA
target sites and functions as a miR-7 sponge to regulate the
expression of human EGFR, SNCA and IRS2 (Hansen et al.,
2013) as well as α-synuclein in PD. If a deficiency occurs in ciRS-
7 “sponging” function, miRNA-7 will be released to potentially
down-regulate AD- relevant targets, such as the ubiquitin protein
ligaseA (UBE2A). UBE-2A is an autophagic, phagocytic protein
essential in the clearance of amyloid peptides in AD and other
progressive inflammatory degenerations of the human CNS,
which is depleted in AD brain (Lukiw, 2013).
CircHomer1a is significantly up-regulated in primary
hippocampal neurons. Strikingly, upregulation of circHomer1-a
could prevent the potential overexpression of Homer1b/c
which may be detrimental to homeostatic synaptic downscaling
(You et al., 2015), indicating that circHomer1a could be
used as a promising therapeutic target for the treatment of
chronic inflammatory pain (Tappe et al., 2006). In addition,
downregulation of Homer1b/c could alleviate cytoplasmic
calcium levels and neural lactate dehydrogenase release,
and ultimately decrease the apoptotic rate after traumatic
neuronal injury (Fei et al., 2014). This is supported by the
fact that regulating the scaffold protein Homer1 may connect
metabotropic glutamate receptors (mGluRs) to the endoplasmic
reticulum (Rickhag et al., 2006). CircPAIP2 is an intron-retained
circRNAs associated with human RNA polymerase II localized
in the nuclei, supporting its potential function in interacting
with U1 small nuclei ribonucleoprotein (Li Z. et al., 2015).
Therefore, upregulating its parental gene PAIP2 in cis may affect
translational inhibition of contextual memory-related genes
through PABP reactivation (Khoutorsky et al., 2013).
Burd et al. (2010) identified circular ANRIL products
emanating from the ANRIL locus and deemed them as
causal variants at 9p21.3 to regulate INK4/ARF expression,
challenging the notion of atherosclerosis risk in association with
modulating ANRIL expression and/or structure (Burd et al.,
2010). However, whether circular ANRIL tweaks epigenetic
regulation in cardiovascular risk is not clearly understood yet
(Perkel, 2013).
CircRNAs possibly serve as a layer of regulation in protein
synthesis (Chen and Sarnow, 1995; Hentze and Preiss, 2013).
They may bind to mRNA directly to drive translation inside
cells, or bind to RNA-binding proteins (RBPs) such as Argonaute,
RNA polymerase II and MBL and play a role in the regulation of
alternative splicing (Westholm et al., 2014). All these potential
mechanisms remain to be further investigated in CNS.
CircRNAs as Potential Biomarkers for
Diagnosis and of Prognosis in CNS
Disorders
Seeking biomarkers for diagnosis and prognosis of CNS diseases
and to guide treatment is always one of top priorities in clinic
research. As we know, the network of circRNAs, microRNAs,
piRNA and lncRNAs needs to maintain a delicate dynamic
balance to regulate cellular homeostasis, many of them have
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FIGURE 1 | The network of circRNAs, microRNAs, piRNA and lncRNAs. Coding sequence (CDS) and 3′ untranslated region (UTR) are followed by polyA tail.
MicroRNAs are bound with Argonaute (Ago) proteins and also bound to partially complementary sites in the 3′UTR. Similarly, piRNAs loaded in PIWI associate with
the 3′UTR by full complementarity binding. Ago-miRNA activity is further modulated by adjacent RNA-binding proteins (RBPs), presumably by interacting with target
proteins. Three types of circRNAs are spliced from DNA, including exon-shuffling-derived circRNA (ecRNA), which is only comprised of exons; circular intronic RNA
(ciRNA), which is the byproduct formed by intron after pos-transcription; and elciRNAs (exon–intron RNAs), which is consisted of exon and retained intron, and long
intron with reverse complementary sequences flanking the joined exons. CiRNAs and elciRNAs can interact with transcription machinery (RNA Pol II and U1 snRNP)
to promote their parent gene expression in the nuclei. Long non-coding RNA (LncRNA) could also act as competitive endogenous RNAs to compete for microRNA
binding.
recently been studied extensively as biomarkers in CNS disorders.
Once one of them is dysregulated, disease may occur (Figure 1)
(Hentze and Preiss, 2013; Chen and Yang, 2015; Shen et al., 2015;
Weiss et al., 2015). So measuring this network as a diagnostic
marker and a possible marker for treatment monitoring is
constantly promoted in recent studies. For example, circulating
U2 small nuclear RNA fragments has been proposed to be
a novel diagnostic biomarker for primary CNS lymphoma
(Baraniskin et al., 2016). Long non-codingRNAs (lncRNA) and
circulating miRNAs can be used as biomarkers for CNS disorders,
such as lncRNA Sox2OT for AD and PD, lncRNA NEAT1
for Huntington’s disease (HD) (Wu et al., 2013), miR-451 for
amyotrophic lateral sclerosis ALS (Grasso et al., 2014), miRNA
200 family for glioblastoma (Areeb et al., 2015), miR-326 for MS
(Fenoglio et al., 2012) and serum miR-210 for cerebral ischemia
and stroke (Ouyang et al., 2013). Piwi-interacting RNAs (piRNA)
largely exert effects on transcription and genomic maintenance,
expression of which in adult male spontaneous hypertensive rats
were examined 24 h after focal ischemia. It was revealed that of
∼40,000 piRNAs analyzed, 105 piRNAs were significantly altered
in cerebral cortex with 54 upregulated and 51 downregulated
(Dharap et al., 2011). It was also observed that 4,527 of 15,849
total mouse circRNAs observed overlap with human circRNAs,
and 11,322 of 15,849 were evolutionary conserved (Rybak-Wolf
et al., 2015). These circRNAs are more stable than linear-RNAs,
indicating circRNAs themselves could serve as biomarkers of
CNS disorders (Qu et al., 2015).
Hypoxia additionally regulates back-splicing and generation
of circRNAs. cZNF292 exhibits a proangiogenic function in
endothelium (Boeckel et al., 2015) while the parental gene
ZNF292s intron related with entorhinal cortical volume is
associated with one AD-specific single-nucleotide polymorphism
(SNP) (Furney et al., 2011).
Synapse dysfunction is a main contributor to CNS diseases
(Dalkara and Alarcon-Martinez, 2015; Pasqualetti et al., 2015),
whereas circRNAs are strongly enriched in synaptoneurosomes
compared to the whole-brain lysate and cytoplasm (Rybak-Wolf
et al., 2015). This inspires many to study the synaptoneurosomes-
related aberrant circRNA released for CNS diseases diagnosis.
Recent studies demonstrated aberrant circRNA expression in
a disease condition-specific transcriptome analysis in blood
cells themselves, or either active or passive release from
diseased tissues (Memczak et al., 2015). Moreover, exosomes
(<1000 nt) released by endothelial cells and neurons participate
in angiogenic sprouting and support neuron activity, respectively
(Chivet et al., 2013; Haqqani et al., 2013). Normally, the
high stability of exo-circRNA (350 nt) (Li Y. et al., 2015) is
due to the protection of exosomes or some specific sequence
features or due to protein partner binding of circularing
circRNAs (Li Y. et al., 2015). CNS diseases may compromise
the BBB structure resulting in loss of small molecules such
as microRNAs (18-23 nt) (Sun et al., 2013; Dalkara and
Alarcon-Martinez, 2015) and microvesicles with an average
diameter of 100 nm into blood or CSF, suggesting CNS
circRNAs transporting out of the BBB (Faure et al., 2006).
Overall, these data suggest a potential non-invasive tool to get
CNS disease information from blood or CSF. Indeed, their
abundance and specific expression patterns suggest that these
molecules may have additional functions which remain to be
discovered.
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CONCLUSION
Although circRNAs possess potential value as non-invasive
clinical biomarkers for CNS disorders, a considerable amount
of future work remain to be invested. It is important to
accurately identify with high sensitivity which circRNAs
are specifically dys-regulated in disease situations. For
clinical application, the study population needs to be
phenotypically well-defined. In addition, these circRNA
biomarkers may be combined with other biomarkers and
imaging tools to improve the power for diagnosis and
prognosis. Furthermore, longitudinal understanding of the
fundamental factors that influence miRNA expression such as
age, environmental factors, and co-morbid conditions should
also be considered.
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